Skip to main content
. 2018 Aug 28;24(32):3567–3582. doi: 10.3748/wjg.v24.i32.3567

Table 1.

Currently approved biologic treatments for inflammatory bowel diseases[16,117,118]

Medication Route of administration (IV, SC, PO) Approved dose
Infliximab IV Induction: 5-10 mg/kg (weeks 0, 2, and 6) Maintenance: 5-10 mg/kg every 4-8 wk
Adalimumab SC Induction: 160 mg (week 0), 80 mg (week 2) Maintenance: 40 mg every 7-14 d
Golimumab SC Induction: 200 mg (week 0), 100 mg (week 2) Maintenance: 100 mg every 4 wk
Certolizumab SC Induction: 400 mg (weeks 0, 2, and 4) Maintenance: 400 mg every 4 wk
Vedolizumab IV Induction: 300 mg (weeks 0, 2, and 6) Maintenance: 300 mg every 4-8 wk
Ustekinumab IV SC Induction: < 55 kg: 260 mg 55-85 kg: 390 mg > 85 kg: 520 mg Maintenance: 90 mg every 8 wk